Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 8;31(38):e202500685.
doi: 10.1002/chem.202500685. Epub 2025 Apr 26.

Total Synthesis of Kanamycins

Affiliations

Total Synthesis of Kanamycins

Kanae Hosomi et al. Chemistry. .

Abstract

Structurally modified aminoglycosides, such as kanamycin, have shown promise as antibiotics and premature termination codon read-through drugs to fight against drug-resistant bacteria and to treat genetic diseases, respectively. Therefore, research on developing and discovering aminoglycoside antibiotics has recently increased. However, synthetic strategies for controllably positioning the two 1,2-cis-glycoside moieties on the symmetrical structure of kanamycin have not yet been established. Herein, we report on a novel route for the total synthesis of kanamycins A and B via regio- and stereoselective introduction of 1,2-cis-glycosidic linkages as the key step. We successfully synthesized α(1,6)-linked glycoside using a 1,2-anhydro donor and 2-deoxy-myo-inositol 1,3,5-orthoformate acceptor in the presence of a boronic acid catalyst via desymmetric boron-mediated aglycon delivery. In addition, we also synthesized α(1,4)-linked glycoside using its corresponding trichloroacetimidate donor.

Keywords: boron‐mediated aglycon delivery; desymmetrization; glycosylation; kanamycin; total synthesis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Chemical structures of aminoglycoside antibiotics.
Figure 2
Figure 2
(A) Nakajima's and (B) Umezawa's total synthesis of kanamycin A. (C) Synthesis of kanamycin analogs using neomycin B. (D) Desymmetric BMAD reaction of 1,2‐anhydro donor 14 and meso‐diol 15. LG = leaving group, Cbz = benzyloxycarbonyl, Bn = benzyl, Ac = acetyl, TBS = tert‐butyldimethylsilyl, Ar = aryl.
Scheme 1
Scheme 1
Retrosynthetic analysis of kanamycin A.
Scheme 2
Scheme 2
(A) Synthetic scheme of meso‐diol 24. (B) Synthetic scheme of 1,2‐anhydro donor 25. (C) Desymmetric BMAD reaction of 24 and 25. Et = ethyl, Ts = toluenesulfonyl, DMF = N,N‐dimethylformamide, Tf = trifluoromethanesulfonyl, AIBN = 2,2′‐azobis(isobutyronitrile), TBAI = tetra‐n‐butylammonium iodide, Me = methyl, MeCN = acetonitrile, DCM = dichloromethane, THF = tetrahydrofuran, DMDO = dimetyldioxyrane.
Scheme 3
Scheme 3
(A) Total synthesis of kanamycin A (1) and (B) kanamycin B (2). DIPEA = N,N‐diisopropylethylamine, DMAP = N,N‐4‐dimethylaminopyridine, Bz = benzoyl, Ph = phenyl, TMSOTf = trimethylsilyl trifluoromethanesulfonate, MS = molecular sieves, TMSOK = potassium trimethylsilanolate.

References

    1. Umezawa H., Ueda M., Maeda K., Yagishita K., Kondo S., Okami Y., Utahara R., Osato Y., Nitta K., Takeuchi T., J. Antibiot. 1957, 10, 181. - PubMed
    1. Umezawa H., Adv. Carbohydr. Chem. Biochem. 1974, 30, 183. - PubMed
    1. Vakulenko S. B., Mobashery S., Clin. Microbiol. Rev. 2003, 16, 430. - PMC - PubMed
    1. Ramirez M. S., Nikolaidis N., Tolmasky M. E., Front. Microbiol. 2013, 4, 121. - PMC - PubMed
    1. Kawaguchi H., Naito T., Nakagawa S., Fujisawa K.‐I., J. Antibiot. 1972, 25, 695. - PubMed

MeSH terms

LinkOut - more resources